Progress of ¹⁸F-flurpiridaz in Clinical Trials.

ABSTRACT: ¹⁸F-flurpiridaz is a novel positron emission computed tomography (PET) tracer in ongoing clinical trials in United States and Japan. A phase III prospective, open-label, multi-center study to assess the feasibility of ¹⁸F-flurpiridaz was reported by Maddahi et al. in patients with known or suspected coronary artery disease (CAD) in 2020 in United States (1). ¹⁸F-flurpiridaz binds to mitochondrial complex 1 and would distribute to the myocardium with its higher extraction fraction than those in single-photon emission computed tomography (SPECT) tracers (2). In that phase III trial, 795 participants with known or suspected CAD showed that sensitivity of ¹⁸F-flurpiridaz PET (for detection of ≥50% stenosis by invasive coronary angiography) was 71.9%,

SUBMITTER: Matsumoto N 

PROVIDER: S-EPMC10696143 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature